Nengte Technology: Under investigation by the CSRC for suspected information disclosure violations

On the evening of April 1, Nengte Technology (002102.SZ) disclosed an announcement regarding receiving a filing notice from the China Securities Regulatory Commission.

The announcement stated that Hubei Nengte Technology Co., Ltd. received on April 1, 2026, a “Filing Notice” issued by the China Securities Regulatory Commission (hereinafter referred to as the “CSRC”) (File No.: 证监立案字0052026003), and the CSRC decided to file the case against the company for alleged violations and irregularities in information disclosure, pursuant to laws and regulations including the Securities Law of the People’s Republic of China, the Administrative Penalty Law of the People’s Republic of China, and others.

At present, the company’s production and business operations are operating normally and in an orderly manner. During the filing investigation period, the company will actively cooperate with the CSRC’s investigation efforts and will strictly fulfill its information disclosure obligations in a timely manner in accordance with relevant laws, regulations, and regulatory requirements.

In the announcement, the company did not disclose any detailed information about the alleged violations and irregularities in information disclosure.

According to available information, Hubei Nengte Technology Co., Ltd. was listed on the Shenzhen Stock Exchange in 2006. Its主营业务 (main businesses) include pharmaceutical intermediates, vitamin E and its intermediates, the plastic trading e-commerce business, and other businesses.

A prior performance forecast released by the company for 2025 showed that it expected net profit attributable to shareholders of the listed company of RMB 200 million to RMB 250 million for FY2025, representing an increase of 134.01% to 142.51% year over year, and that it would turn losses into profits. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was expected to be RMB 320 million to RMB 390 million, representing an increase of 162.06% to 175.63% year over year.

The main reasons for the company’s performance changes include: a significant increase in performance for the vitamin E business, which is expected to bring profits of no less than RMB 660 million; the pharmaceutical intermediates business performing below expectations, with profit affected in particular by the sales volume and market competition situation of the intermediates of montelukast sodium and rosuvastatin; profit reduction due to the sale of a gold mine of RMB 48.87 million; and litigation-related provision for losses, which is expected to reduce the company’s 2025 profits by RMB 79.59 million.